| Name | Title | Contact Details |
|---|---|---|
Steve Bosrock |
Vice President of Marketing | Profile |
Tom Wilder |
President and Chief Executive Officer | Profile |
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.
Pharmacists Mutual Companies is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
BIND Biosciences, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Applied Genomics is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.